Evidence map›Paper›PMID 14577583›Full record

ArticleMolecular and cellular biochemistry2003

Resistance to thapsigargin-induced intracellular calcium mobilization in a multidrug resistant tumour cell line.

Karen Wagner-Souza, Juliana Echevarria-Lima, Louise A P Rodrigues, Marcelo Reis, Vivian M Rumjanek

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Karen Wagner-SouzaLaboratório de Imunologia Tumoral, Departamento de Bioquímica Medica, Universidade Federal do Rio de Janeiro, Brazil.
Juliana Echevarria-Lima
Louise A P Rodrigues
Marcelo Reis
Vivian M Rumjanek
Universidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A multidrug resistant (MDR) cell line, derived from the human leukaemic cell K562 and selected for its resistance to Vincristine, was shown to be resistant to Thapsigargin (TG). A concentration of 50 nM TG was toxic to K562 cells whereas the MDR cell line, known as Lucena I cells, survived unaffected for up to seven days in culture. Similarly, no intracellular Ca2+ mobilization was observed in the MDR cell line treated with TG. This effect was not a result of TG extrusion by P glycoprotein (Pgp), as no mobilization was observed even in the presence of the Pgp inhibitors Verapamil (5 microM) and Cyclosporin A (0.16 microM). In the present study, both cell lines expressed comparable levels of Bcl-2 making it unlikely that Bcl-2 was involved in this process. Similarly, no overexpression of the endoplasmic reticulum Ca2+ ATPase (SERCA) could be detected in the MDR cell line and Ca2+ uptake by vesicles of the two cell types were equally sensitive to TG. These results confirm that MDR cells do not mobilize Ca2+ in the presence of TG but go against the possibility that this might be due to TG extrusion or to the overexpression of a resistant SERCA isoform.

Indexed as

Drug Resistance, MultipleDrug Resistance, NeoplasmAntineoplastic AgentsCalciumCalcium-Transporting ATPasesHumansK562 CellsProto-Oncogene Proteins c-bcl-2Sarcoplasmic Reticulum Calcium-Transporting ATPasesThapsigarginAntineoplastic AgentsCalciumCalcium-Transporting ATPasesProto-Oncogene Proteins c-bcl-2Sarcoplasmic Reticulum Calcium-Transporting ATPasesThapsigargin

Identifiers

PMID14577583
OpenAlexW102984782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.